These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 3497146)

  • 1. Susceptibility of cefotetan and Sch 34343 to beta-lactamases produced by strains of Bacteroides that hydrolyse cefoxitin or imipenem.
    Andrew JH; Greenwood D
    J Antimicrob Chemother; 1987 May; 19(5):591-5. PubMed ID: 3497146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative susceptibility of cefminox and cefoxitin to beta-lactamases of Bacteroides spp.
    Soriano F; Edwards R; Greenwood D
    J Antimicrob Chemother; 1991 Jul; 28(1):55-60. PubMed ID: 1769943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity, beta-lactamase stability and beta-lactamase inhibition of cefotetan and other 7-alpha-methoxy beta-lactam antimicrobials.
    Jones RN; Wilson HW
    Diagn Microbiol Infect Dis; 1983 Mar; 1(1):71-83. PubMed ID: 6323095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-lactamases of type culture strains of the Bacteroides fragilis group and of strains that hydrolyse cefoxitin, latamoxef and imipenem.
    Eley A; Greenwood D
    J Med Microbiol; 1986 Feb; 21(1):49-57. PubMed ID: 3485198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-antibiotic effect in Bacteroides fragilis group.
    Siverhus DJ; Edmiston CE; Clausz JC; Goheen MP
    Ann Clin Lab Sci; 1988; 18(4):326-36. PubMed ID: 3165611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of beta-lactamases in clinical isolates of Bacteroides.
    Eley A; Greenwood D
    J Antimicrob Chemother; 1986 Sep; 18(3):325-33. PubMed ID: 3490466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative stability of meropenem against beta-lactamases from Bacteroides spp.
    Edwards R; Brown J; Greenwood D
    Chemotherapy; 1993; 39(6):390-3. PubMed ID: 8222865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-lactamases with high activity against imipenem and Sch 34343 from Aeromonas hydrophila.
    Shannon K; King A; Phillips I
    J Antimicrob Chemother; 1986 Jan; 17(1):45-50. PubMed ID: 3485091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of beta-lactamases on the antibacterial activity of carumonam and aztreonam against Klebsiella sp. in comparison with 4 other beta-lactams].
    Labia R; Morand A; Pitton JS; Philippin JL; Fournier P
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):796-9. PubMed ID: 3309817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of new beta-lactam antibiotics on cefoxitin-resistant strains of Bacteroides fragilis.
    Dornbusch K; Olsson-Lijequist B; Nord CE
    J Antimicrob Chemother; 1980 Mar; 6(2):207-16. PubMed ID: 6966626
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.
    Owens WE; Finegold SM
    Antimicrob Agents Chemother; 1983 Apr; 23(4):626-9. PubMed ID: 6305265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
    Brown JE; Del Bene VE; Collins CD
    Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of anaerobic bacteria to Sch 34343 and other beta-lactam antibiotics.
    Jacobus NV; Tally FP; Gorbach SL
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():189-91. PubMed ID: 4030547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of Sch 34343 against Gram-negative bacteria producing characterized beta-lactamases.
    Dornbusch K; Frolander F; Cacciapuoti AF; Naples L; Hare RS; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():85-97. PubMed ID: 3897175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
    Aldridge KE; Henderberg A; Sanders CV
    J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.
    Ayers LW; Jones RN; Barry AL; Thornsberry C; Fuchs PC; Gavan TL; Gerlach EH; Sommers HM
    Antimicrob Agents Chemother; 1982 Nov; 22(5):859-77. PubMed ID: 6983862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of cefotetan, a new cephamycin derivative, compared with that of other beta-lactam compounds.
    Wise R; Andrews JM; Hancox J
    Antimicrob Agents Chemother; 1982 Mar; 21(3):486-91. PubMed ID: 6954875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cephamycin inactivation due to enzymatic hydrolysis by beta-lactamase from Bacteroides fragilis.
    Yotsuji A; Minami S; Kakizawa H; Yasuda T; Takai A; Saikawa I; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1985 Dec; 28(6):773-7. PubMed ID: 3878690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the activity of imipenem and beta-lactams combined with sulbactam and clavulanic acid in beta-lactamase-producing strains of Bacteroides fragilis.
    Martín MA; Castillo AM; Liébana J; Marín A; Alados JC; Piédrola G
    J Hyg Epidemiol Microbiol Immunol; 1991; 35(2):189-97. PubMed ID: 1940333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms responsible for reduced susceptibility to imipenem in Bacteroides fragilis.
    Edwards R; Greenwood D
    J Antimicrob Chemother; 1996 Dec; 38(6):941-51. PubMed ID: 9023641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.